Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Subjective complaints of poor near vision that impact activities of daily living~Exclusion Criteria~Uncontrolled systemic disease~Any clinical condition or previous surgery that might affect the absorption, distribution, biotransformation, or excretion of AGN-190584. History of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery, radial keratotomy, or any intraocular surgery. However, participants with history of photorefractive keratectomy (PRK) or laser-assisted in situ keratomileusis (LASIK) with corrected distance visual acuity (CDVA) meeting inclusion criteria will be allowed to enroll.~Known allergy or sensitivity to the study intervention or its components or other cholinergic agonist medications~Concurrent use of any topical ophthalmic medications, including artificial tears, other than the study intervention during the course of the study~Concurrent use of temporary or permanent punctal plugs or history of punctal cautery in one or both eyes~Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study~Participation in a blood or plasma donation program within 30 days prior to study intervention administration~Severe dry eye disease (defined as total corneal staining ≥ grade 3 on the 5-point Oxford scale and an ocular surface disease index (OSDI) score of \> 33) at the screening visit~Corneal abnormalities (including keratoconus, corneal scar, Fuchs' endothelial dystrophy, guttata, or edema) in either eye that are likely to interfere with visual acuity~Narrow iridocorneal angles (Shaffer grade ≤ 2 or lower on gonioscopy examination), history of angle-closure glaucoma, or previous iridotomy~History of iris trauma, Adie's tonic pupil, abnormal pupil shape in either eye, or anisocoria \> 1 mm between pupils under mesopic conditions at the screening visit~Lens opacity in either eye that is determined to cause significant disturbance of the central visual axis on screening biomicroscopy~Diagnosis of any type of glaucoma or ocular hypertension~Bifocal or multifocal spectacles or contact lenses for habitual correction. Participants willing to wear study-provided monofocal correction (either spectacles or contact lenses) during the study can be enrolled~Abnormal and clinically significant results according to the investigator or designee, on physical/ophthalmic examination or medical history~Females who are pregnant, nursing, or planning a pregnancy during the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Vehicle (Type: PLACEBO_COMPARATOR): Participants received one drop of vehicle in each eye, once daily, for up to 30 days.
- Pilocarpine HCl Ophthalmic Solution (Type: EXPERIMENTAL): Participants received one drop of pilocarpine HCl ophthalmic solution 1.25% in each eye, once daily, for up to 30 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete